Subscribe To

Price Alert Latest News Economic Calendar News

LGND / Ligand to Report Second Quarter Financial Results on August 8

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand's CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg. Conference Call and Webcast Information What: Ligand conferenc Read More

Demo Live Account See Partner Details

Content Topics

Ligand

Report

Second

Quarter

Financial

Results

August

Stock

LGND

Posted: Jul 22 2022, 16:08

Author Name: Business Wire

LGND News

By Zacks Investment Research
November 1, 2023

Ligand Pharmaceuticals (LGND) Laps the Stock Market: Here's Why

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $53.30, indicating a +1.93% shift from the previous trading day.

By Zacks Investment Research
October 24, 2023

Why Ligand Pharmaceuticals (LGND) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Pre

By Zacks Investment Research
October 20, 2023

Ligand Pharmaceuticals (LGND) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $52.09, denoting a -1.31% change from the preceding trading day.

By Zacks Investment Research
October 9, 2023

Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $58.84, indicating a +1.19% shift from the previous trading day.

By Zacks Investment Research
October 9, 2023

Will Ligand (LGND) Beat Estimates Again in Its Next Earnings Report?

Ligand (LGND) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat i

By Zacks Investment Research
September 28, 2023

Ligand (LGND) Acquires Certain Assets of Novan for $12.2M

Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform

By Zacks Investment Research
September 19, 2023

Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View

Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own

By Seeking Alpha
September 1, 2023

Ligand: Nothing Exciting Stands Out

Ligand Pharmaceuticals Incorporated generates revenue through licensing technologies, contractual fees, and the sale of Captisol, a modified cyclodext

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.